{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["47(1)"],"submitter":["Yang X"],"pubmed_abstract":["Lupus nephritis (LN) is a frequent and serious complication of systemic lupus erythemosus (SLE). Both innate and adaptive immunity play essential roles in the initiation and progression of LN. B-lymphocyte stimulator (BLYS) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis factor superfamily, bind to receptors such as B-cell activating factor receptor 3 (BR3), transmembrane activator and CAML interactor protein (TACI), and B-cell maturation antigen (BCMA). BLYS and APRIL are often overexpressed in LN, showing a positive correlation with disease activity. Therapeutic targeting of BLYS/APRIL has demonstrated efficacy in reducing LN activity. Traditional immunosuppressants often have multiple contraindications and side effects due to their broad immune-suppressing eff"],"journal":["Renal failure"],"pagination":["2561791"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12624907"],"repository":["biostudies-literature"],"pubmed_title":["Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL."],"pmcid":["PMC12624907"],"pubmed_authors":["Yang X","Lv J","Chen Q","Liu XJ","Deng Q","Liu S","Zeng Y","Zhou Y","Wang Y","Wen D","Li L"],"additional_accession":[]},"is_claimable":false,"name":"Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL.","description":"Lupus nephritis (LN) is a frequent and serious complication of systemic lupus erythemosus (SLE). Both innate and adaptive immunity play essential roles in the initiation and progression of LN. B-lymphocyte stimulator (BLYS) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis factor superfamily, bind to receptors such as B-cell activating factor receptor 3 (BR3), transmembrane activator and CAML interactor protein (TACI), and B-cell maturation antigen (BCMA). BLYS and APRIL are often overexpressed in LN, showing a positive correlation with disease activity. Therapeutic targeting of BLYS/APRIL has demonstrated efficacy in reducing LN activity. Traditional immunosuppressants often have multiple contraindications and side effects due to their broad immune-suppressing eff","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T16:33:38.428Z","creation":"2026-05-18T03:13:03.591Z"},"accession":"S-EPMC12624907","cross_references":{"pubmed":["41249101"],"doi":["10.1080/0886022X.2025.2561791"]}}